Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Interstitial lung diseases; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 Status changed from not yet recruiting to recruiting.
- 06 May 2016 New trial record